exhibit 10. 2 pursuant to 17 cfr 20. 24b - 2, confidential information has been omitted in places marked " * * * " and has been filed separately with the securities and exchange commission pursuant to a confidential treatment request with the commission. pursuant to 17 cfr 20. 24b - 2, confidential information has been omitted in places marked " * * * " and has been filed separately with the securities and exchange commission pursuant to a confidential treatment request with the commission. statement of work biocryst pharmaceuticals contract hhso100201500007c bcx4430 nda enabling cmc and non - clinical toxicology studies preamble independently and not as an agent of the government, the contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the government as needed to perform the statement of work submitted in response to the barda broad agency announcement ( baa ) cbrn - baa - 10 - 100 - sol - 00013. the government reserves the right to modify the milestones, progress, schedule, budget, or deliverables to add or delete deliverables, process, or schedules if the need arises. because of the nature of this research and development ( r & d ) contract and the complexities inherent in this and prior programs, at designated milestones the government will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made. overall objectives and scope the overall objective of this contract is to advance the development of bcx4430, a novel small molecule nucleoside with broad spectrum antiviral activity being developed for diseases caused by rna pathogens. bcx4430, an inhibitor of viral rna – dependent rna polymerase ( rdrp ), is the lead compound in our broad - spectrum antiviral program to meet the need for a parenteral, direct - acting antiviral medical countermeasure ( mcm ) having efficacy across multiple viruses. the scope of work for this contract includes preclinical and manufacturing development activities that fall into the following areas : manufacturing of clinical trial material, manufacturing process improvements and development, non - clinical toxicology studies ; and all associated regulatory, quality assurance, management, and administrative activities. the proposed activities take into account the ebola virus disease ( evd ) outbreak in west africa. the r & d effort will contribute toward an nda filing for bc